scholarly journals Shifting from Village-Based Networks to Locally Generated Networks: Undocumented Mexican Agricultural Workers Who Use/Used Hard Drugs

2017 ◽  
Vol 2017 ◽  
pp. 1-13
Author(s):  
Keith V. Bletzer

Hardships that face transmigrants working in agriculture include the potential for drug use. Reliant on village-based networks that facilitate border crossing and developing a plan for a destination within this country, transmigrants who try new drugs/alcohol and/or continue on accustomed drugs/alcohol are facilitated in these endeavors through locally generated networks as alternative forms of access and support. Seven cases of undocumented men from Mexico are reviewed to show how use of illicit drugs is minimally affected by economic success and time in the United States, or village-based networks that first facilitated entry into this country. Prior conditions, especially childhood difficulties and search for socioeconomic autonomy, precipitate new and/or continuing drug use within the United States on this side of the border, where both forms of drug use are facilitated by locally generated networks.

Author(s):  
Alfred W. McCoy

The current war on drugs being waged by the United States and United Nations rests upon a fundamental misunderstanding of the global nar­cotics traffic. In 1998, for example, the White House issued a National Drug Con­trol Strategy, proclaiming a 10-year program “to reduce illegal drug use and avail­ability 50 percent by the year 2007,” thereby achieving “the lowest recorded drug-use rate in American history.” To this end, the U.S. program plans to reduce foreign drug cultivation, shipments from source countries like Colombia, and smuggling in key transit zones. Although this strategy promises a balanced attack on both supply and demand, its ultimate success hinges upon the complete eradi­cation of the international supply of illicit drugs. “Eliminating the cultivation of il­licit coca and opium,” the document says in a revealing passage, “is the best ap­proach to combating cocaine and heroin availability in the U.S.” (U.S. Office of National Drug Control Policy 1998: 1, 23, 28). Similarly, in 1997 the new head of the United Nations Drug Control Program, Dr. Pino Arlacchi, announced a 10-year program to eradicate all illicit opium and coca cultivation, starting in Afghanistan. Three years later, in the United Nation’s World Drug Report 2000, he defended prohibition’s feasibility by citing China as a case where “comprehensive narcotics control strategies . . . succeeded in eradicat­ing opium between 1949 and 1954”— ignoring the communist coercion that al­lowed such success. Arlacchi also called for an “end to the psychology of despair” that questions drug prohibition, and insisted that this policy can indeed produce “the eradication of coca and opium poppy production.” Turning the page, however, the reader will find a chart showing a sharp rise in world opium production from 500 tons in 1981 to 6,000 tons in 2000— a juxtaposition that seems to challenge Ar-lacchi’s faith in prohibition (Bonner 1997; Wren 1998a, 1998b; United Nations 2000d, 1–2, 24). Examined closely, the United States and United Nations are pur­suing a drug control strategy whose success requires not just the reduction but also the total eradication of illicit narcotics cultivation from the face of the globe. Like the White House, the United Nations Drug Control Program (UNDCP) re­mains deeply, almost theologically committed to the untested proposition that the prohibition of cultivation is an effective response to the problem of illicit drugs.


2003 ◽  
Vol 29 (4) ◽  
pp. 525-542
Author(s):  
Merri C. Moken

The use of pharmaceutical products in the United States has increased more than the use of any other health resource from 1960 to 1990. In excess of 9,600 drugs were on the market in 1984, and the Food and Drug Administration (“FDA”) approves approximately 30 new drugs and countless new applications for alterations of already existing drugs each year. In 2001, the $300 billion pharmaceutical industry sold $154 billion worth of prescription drugs in the United States alone, nearly doubling its $78.9 billion in sales in 1997. With such a rapid increase in market domination and expenditures, the U.S. government and many hospitals have focused their attention on the sales and pricing practices of pharmaceutical companies, as well as other potential factors contributing to these escalating prices. One such cause of the steadily increasing prices of brand name pharmaceuticals is the sale of fake or counterfeit pharmaceuticals (also called “look-alike” drugs).


2013 ◽  
Vol 8 (1) ◽  
pp. 82-90 ◽  
Author(s):  
Geraldine Pierre ◽  
Roland J. Thorpe ◽  
Gniesha Y. Dinwiddie ◽  
Darrell J. Gaskin

This article sought to determine whether racial disparities exist in psychotropic drug use and expenditures in a nationally representative sample of men in the United States. Data were extracted from the 2000-2009 Medical Expenditure Panel Survey, a longitudinal survey that covers the U.S. civilian noninstitutionalized population. Full-Year Consolidated, Medical Conditions, and Prescribed Medicines data files were merged across 10 years of data. The sample of interest was limited to adult males aged 18 to 64 years, who reported their race as White, Black, Hispanic, or Asian. This study employed a pooled cross-sectional design and a two-part probit generalized linear model for analyses. Minority men reported a lower probability of psychotropic drug use (Black = −4.3%, 95% confidence interval [CI] = [−5.5, −3.0]; Hispanic = −3.8%, 95% CI = [−5.1, −2.6]; Asian = −4.5%, 95% CI = [−6.2, −2.7]) compared with White men. After controlling for demographic, socioeconomic, and health status variables, there were no statistically significant race differences in drug expenditures. Consistent with previous literature, racial and ethnic disparities in the use of psychotropic drugs present problems of access to mental health care and services.


2018 ◽  
Vol 59 ◽  
pp. 71-80 ◽  
Author(s):  
Michael G. Vaughn ◽  
Christopher P. Salas-Wright ◽  
David Cordova ◽  
Erik J. Nelson ◽  
Lisa Jaegers

Trauma ◽  
2021 ◽  
pp. 146040862110443
Author(s):  
Nikan K Namiri ◽  
Austin W Lee ◽  
Gregory M Amend ◽  
Jason Vargo ◽  
Benjamin N Breyer

Introduction Bicycles and electric scooters (e-scooters) are convenient and accessible means of transportation. Participant safety is contingent on available infrastructure and safe riding practices including not riding while intoxicated. Understanding national prevalence and injury characteristics of bicycle and e-scooter riders who ride while intoxicated may promote awareness campaigns for safe riding practices and decrease morbidity. Methods The National Electronic Injury Surveillance System (NEISS) provides national estimates of injuries that present to emergency departments across the United States. We obtained case information on admitting status, body part injured, diagnosis of injury, age, sex, alcohol usage, and drug usage. We then queried NEISS for injuries related to bicycles and e-scooters in 2019. Results A weighted total of 270,571 (95% confidence interval (CI): 204,517–336,625) bicycle injuries occurred in the United States during 2019; alcohol and drug use were associated with 7% (95% CI: 6–9) and 2% (95% CI: 2–3) of all injuries, respectively. Twenty-four percent (CI: 18--31) of alcohol- and 29% (95% CI: 20–41) of drug-related bicycle injuries resulted in hospital admissions, compared to 15% (95% CI: 12–17) of non–alcohol- and 15% (95% CI: 13–18) of non–drug-related injuries ( p < .001 and p = .002, respectively). A total of 28,702 (95% CI: 13,975–43,428) e-scooter injuries occurred in 2019; alcohol and drug use were associated with 8% (95% CI: 5–12) and 1% (95% CI: 1–2) of injuries, respectively. Sixty percent (95% CI: 47–72) of alcohol-related e-scooter injuries resulted in head trauma, compared to 28% (95% CI: 24–32) of non–alcohol-related injuries ( p < .001). Conclusions Intoxication is associated with increasingly severe injuries, hospital admissions, and head trauma in bicycle and e-scooter riders. The findings support awareness campaigns to educate riders about risky practices, improve non-auto infrastructure, and promote helmet usage.


2018 ◽  
Vol 55 ◽  
pp. 207-214 ◽  
Author(s):  
Annie Ristuccia ◽  
Caleb LoSchiavo ◽  
Perry N. Halkitis ◽  
Farzana Kapadia

2016 ◽  
Vol 51 (13) ◽  
pp. 1681-1692 ◽  
Author(s):  
Christopher P. Salas-Wright ◽  
Michael G. Vaughn ◽  
Jennifer M. Reingle Gonzalez ◽  
Qiang Fu ◽  
Trenette Clark Goings

Sign in / Sign up

Export Citation Format

Share Document